Events

London – 25 November 2025 Purespring Therapeutics, a precision nephrology company leading the development of targeted, first-in-class genetic therapies to preserve kidney function, today announced…

New information to be presented on the study design and methodology of Purespring’s Phase I/II trial of PS-002, an AAV-based therapy delivering the complement factor…

Members of the Purespring management team will present at Chardan’s 9th Annual Genetic Medicines Conference. London – 14 October 2025 Purespring Therapeutics, a precision nephrology…

Members of the Purespring management team will participate in the 2025 Bank of America Healthcare Trailblazers Private Company Conference. London – 10 September 2025 Purespring…

EMA designation provides orphan status to medicines being developed for rare conditions that are intended for the diagnosis, prevention or treatment of diseases affecting fewer…

Results from the study underpin the potential of Purespring’s lead AAV gene therapy programme, PS-002, as an important novel modality to treat IgAN Data support…

Data establishes the potential of AAV gene therapy to deliver transgenes to the podocyte to replace defective genes or to modulate protein production Data underpin…